compani
 stock weak due anticip ep
slowdown long-term fundament intact
lli stock weak yesterday diabet busi sale fell short expect
particularli jardianc gave littl new inform impact posit
rewind studi could class estim reflect potenti upsid
fourth quarter bring pt potenti catalyst
left expect lli stock range-bound thru year-end howev remain
posit lli long-term fundament given strong comml clinic execut
outsid trulic diabet busi continu see price pressur
basaglar biosimilar glargin main culprit even though diabet lli largest
therapeut segment grew volum y/i perform compani insulin
busi well oral agent tradjenta jardianc partner boehring
ingelheim miss expect combin sale humalog tradjenta jardianc
basaglar miss consensu estim respect us
volum growth off-set anoth price declin management note
percentag point price declin came access volum growth basaglar
medicar part compani continu execut volume-driven growth strategi
nod evolv us drug-pric environ management expect us
price reimburs dynam signific impact busi
continu see new product growth offset compani exposur step-up
medicar part coverag gap increment headwind top-line
rebat discount dynam
rewind wont reveal june american diabet associ
meet leav investor want management field heavi dose question relat
yesterday rewind cv outcom top-lin result trulic respect
increment data point studi data could mean trulic
overal class growth management provid much increment inform continu
character result precedent-set given major patient
cardiovascular diseas rel lower mean glucos level vs previou
outcom trial management plan file label expans trulic base
rewind result expect approv new label rewind data
present american diabet associ meet june san francisco
growth outlook key product remain unchang new product
contribut point volum growth taltz look particularli strong
rel expect beat sale estim y/i volum growth
trulic contribut grow y/i highlight drug profil
categori olumi uptak intern good us uptak appear
limit management attribut earli us plan olumi includ free
sampl physician drive futur sale growth given rel perform key
driver bump taltz estim
lower olumi estim net
effect sale chang littl impact revenu outlook
pain program among key upcom potenti catalyst view tanezumab long-
term safeti efficaci studi like import near-term catalyst
expect data us launch posit chmp opinion emgal
commerci uptak competit dynam cgrp antibodi
watch close also plan submit emgal cluster headach
drug fda breakthrough design ye also one step closer
commerci lasmiditan oral drug acut migrain management host
investor updat decemb get guidanc learn
page analyst certif import disclosur
valuat risk
dcf price target forecast sale profit
use larg pharmaceut compani discount rate termin growth rate
downsid risk includ sustain price pressur diabet immunolog higher-than-
expect rate seriou advers event rpoa long term safeti studi tanezumab
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
